Please login to the form below

Not currently logged in
Email:
Password:

Redx poaches AstraZeneca senior executive

Lisa Anson joins the UK biotech as its CEO

Lisa AnsonDrug discovery and development group Redx Pharma has appointed its new chief executive officer in the form of Lisa Anson.

Anson, who was previously AstraZeneca’s UK president since 2012, also joins Redx’s board of directors, taking up both roles on 1 June.

With a 20-year career with AstraZeneca, Anson has held a variety of senior management roles at the pharmaceutical company, situated in both the US and UK, including global vice president oncology, and vice president of emerging brands, working closely with the research and development teams.

Ian Ross, executive chairman of Redx, said: “Lisa has been tasked by the board to lead the re-launch of the company and to take the steps necessary to build a substantial biotech company built upon an innovative science base, selectively acquiring additional assets.

“Lisa is a consummate business professional, who brings a wealth of relevant experience from the international pharmaceutical and biotech sector and I am confident that she is the right person to grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders."

27th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics